1. Home
  2. HRMY vs HNI Comparison

HRMY vs HNI Comparison

Compare HRMY & HNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • HNI
  • Stock Information
  • Founded
  • HRMY 2017
  • HNI 1944
  • Country
  • HRMY United States
  • HNI United States
  • Employees
  • HRMY N/A
  • HNI N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • HNI Office Equipment/Supplies/Services
  • Sector
  • HRMY Health Care
  • HNI Consumer Discretionary
  • Exchange
  • HRMY Nasdaq
  • HNI Nasdaq
  • Market Cap
  • HRMY 2.1B
  • HNI 2.1B
  • IPO Year
  • HRMY 2020
  • HNI N/A
  • Fundamental
  • Price
  • HRMY $35.99
  • HNI $46.72
  • Analyst Decision
  • HRMY Strong Buy
  • HNI Strong Buy
  • Analyst Count
  • HRMY 9
  • HNI 1
  • Target Price
  • HRMY $55.33
  • HNI $70.00
  • AVG Volume (30 Days)
  • HRMY 531.4K
  • HNI 722.0K
  • Earning Date
  • HRMY 10-28-2025
  • HNI 10-28-2025
  • Dividend Yield
  • HRMY N/A
  • HNI 2.94%
  • EPS Growth
  • HRMY 58.41
  • HNI 30.07
  • EPS
  • HRMY 3.10
  • HNI 3.08
  • Revenue
  • HRMY $772,527,000.00
  • HNI $2,581,500,000.00
  • Revenue This Year
  • HRMY $20.09
  • HNI $5.80
  • Revenue Next Year
  • HRMY $16.74
  • HNI $3.78
  • P/E Ratio
  • HRMY $11.61
  • HNI $15.00
  • Revenue Growth
  • HRMY 17.74
  • HNI N/A
  • 52 Week Low
  • HRMY $26.47
  • HNI $39.76
  • 52 Week High
  • HRMY $41.61
  • HNI $58.42
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 47.09
  • HNI 56.07
  • Support Level
  • HRMY $36.50
  • HNI $44.13
  • Resistance Level
  • HRMY $38.28
  • HNI $45.41
  • Average True Range (ATR)
  • HRMY 0.95
  • HNI 0.87
  • MACD
  • HRMY -0.17
  • HNI 0.45
  • Stochastic Oscillator
  • HRMY 9.84
  • HNI 90.11

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

Share on Social Networks: